Skip to main content
Syndax Pharmaceuticals Inc logo

Syndax Pharmaceuticals Inc — Investor Relations & Filings

Ticker · SNDX ISIN · US87164F1057 LEI · 529900OF94TRHKZVBS87 US Manufacturing
Open in API
Filings indexed 620 across all filing types
Latest filing 2026-06-04 Proxy Solicitation & In…
Country US United States of America
Listing US SNDX

About Syndax Pharmaceuticals Inc

https://syndax.com/

Syndax Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes therapies for various cancers. The company focuses on developing first-in-class and best-in-class treatments for areas with significant unmet medical needs, such as acute leukemias and chronic Graft-versus-Host Disease (GVHD). Its pipeline targets a range of hematological malignancies and solid tumors, utilizing approaches in epigenetics and immunomodulation to create transformative therapies.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement
2026-06-04 English
8-K
Capital/Financing Update Classification · 90% confidence The document is a Form 8-K Current Report announcing the private placement of $250 million aggregate 2.25% Convertible Senior Notes due 2031, detailing the terms of the notes, indenture, conversion features, and expected use of proceeds. This constitutes a financing activity and a change in the company’s capital structure. Therefore, it aligns with the “Capital/Financing Update” category (CAP).
2026-06-04 English
ARS - Syndax Pharmaceuticals Inc (0001395937) (Filer)
Annual Report
2026-04-30 English
DEF 14A - Syndax Pharmaceuticals Inc (0001395937) (Filer)
Proxy Solicitation & Information Statement
2026-04-30 English
10-K - SYNDAX PHARMACEUTICALS INC (0001395937) (Filer)
Annual Report FY 2025
2026-02-26 English
8-K - SYNDAX PHARMACEUTICALS INC (0001395937) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 26, 2026, by Syndax Pharmaceuticals, Inc. It announces the issuance of a press release and a corporate presentation regarding financial results for the quarter and year ended December 31, 2025. The document itself does not contain the financial results but rather furnishes the press release and presentation as exhibits. The length of the document is 3738 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, since this document announces the release of financial results and includes exhibits of a press release and presentation, it should be classified as a Regulatory Filing (RNS) rather than an Earnings Release (ER) or Investor Presentation (IP) itself. The document is primarily an announcement of the release of these materials, not the materials themselves in full detail.
2026-02-26 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.